This message was posted by a user wishing to remain anonymous
Does anyone have experience updating Mod 2 summaries during BLA review? Specifically, I'd like to understand if you have new pivotal data that becomes available during BLA review, should you be revising the respective summary documents to reflect this new information? As a note, FDA has agreed to the Sponsor providing refreshed data, but would like it prior to the 120-day safety/efficacy update.